Retroperitoneal Liposarcoma
Treatment Market – Drivers
The global Retroperitoneal
Liposarcoma Treatment Market is expected to exhibit a moderate growth rate,
owing to low incidence of this disease across the globe. According to the World
Health Organization (WHO) 2016, liposarcoma is the most common type of sarcomas
(cancer of soft tissue) and is classified as a rare disease, which accounts for
around 17-20% of all the cases (2.5 per Mn population) of sarcoma. Furthermore,
rising incidence of genetic disorders is one of the major factors responsible
for the global retroperitoneal liposarcoma treatment market growth. According
to a report published by the Genetics Education Center, University of Kansas
Medical Center, around 15% of all the cancers have an inherited susceptibility
and around 12% of the hospital admissions in the U.S. accounted for the
treatment of genetic causes in 2013. Various other factors contributing to
market growth include changing lifestyle and growing awareness among populace
regarding availability of treatment for liposarcoma through initiatives undertaken
by various organizations. For instance, Liposarcoma Genome Project initiative
by Massachusetts General Hospital Cancer Center conducted research to
understand the differences between well-differentiated and de-differentiated
liposarcoma, to support the development of treatment for the rare disease.
However, high costs associated with the treatment procedures and low
accessibility of the treatment due to rareness of the disease are expected to
be factors hindering the market growth.
Retroperitoneal liposarcoma (RLS)
is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum,
lining of the abdominal space that covers the abdominal organs. Retroperitoneal
liposarcoma grow continuously and may not get diagnosed until they are very
large thus, its prognosis is poor compared to the other subtypes of
retroperitoneal sarcomas.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1861
The reason for the development of
these tumors are still unknown, however, genetic mutation is considered to be
one of the factors leading to the generation of these tumors. Incidence of this
disease is equal in men and women, with a slight predominance of men. This
tumor has no characteristic symptoms and are usually diagnosed during the
advanced stage.
Furthermore, the effectiveness of
radiotherapy or chemotherapy for the treatment of this tumor is not properly
defined, as they are massive in size and might involve adjacent visceral organs
and critical structures. However, affected population who received adjuvant
chemotherapy showed survival benefits and improvement, as compared to patients
who underwent surgery alone. In the case of surgeries, sometimes, preoperative
radiation is given to shrink the tumor. This allows smaller doses of radiation
to a smaller field and make the surgery technically more feasible. The European
Organisation for Research and Treatment of Cancer (EORTC) is currently
conducting a randomized trial comparing 50.4 Gy (Gray-unit to measure radiation
therapy) of pre-operative radiation therapy with short-course radiotherapy,
followed by surgery to direct surgery alone. Thus, continuous researches that
are being conducted for the development of treatment for this disease is
expected to create lucrative opportunities in the retroperitoneal liposarcoma
treatment market during the forecast period.
Retroperitoneal Liposarcoma Treatment
Market - Regional Analysis
On the basis of region, the
global retroperitoneal liposarcoma treatment market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North
America holds the maximum share for retroperitoneal liposarcoma treatment,
owing to increasing research and development of novel therapies and potential
drugs for dedifferentiated liposarcoma. For instance, the Sarcoma Foundation of
America (SFA) aids sarcoma patients by providing funding for research to
private researchers and conducts education campaigns for patients suffering
from various types of sarcomas.
Browse Research Report:
https://www.coherentmarketinsights.com/ongoing-insight/retroperitoneal-liposarcoma-treatment-market-1861
Furthermore, Asia pacific also
generates the significant value in retroperitoneal liposarcoma treatment
market, owing to the presence of significant population suffering from the
disease in this region. For instance, according to the Journal of Blood &
Lymph 2013, in India around 35% of the patients suffering from sarcoma died due
to dedifferentiated liposarcoma.
Retroperitoneal liposarcoma
Treatment Market – Competitor Landscape
Increasing regulatory approvals
by the U.S. FDA for various products manufactured by large companies is
expected to boost the overall growth of the retroperitoneal liposarcoma
treatment market. For instance, in 2015, the U.S. FDA granted priority review
for the New Drug Application (NDA) for YONDELIS (trabectedin), manufactured by
Janssen Research & Development, LLC to treat patients with advanced soft
tissue sarcoma (STS), which includes liposarcoma and leiomyosarcoma subtypes in
77 countries, within North America, Europe, South America, and Asia.
Furthermore, in 2016, Eisai Co., Ltd. received the approval in Japan for its
in-house developed anticancer agent Halaven (eribulin mesylate) for the
treatment of patients suffering from soft tissue sarcoma.
Market players operating in the
global retroperitoneal liposarcoma treatment market include Eli Lilly and
Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva
Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd.,
Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford
Laboratories, and Zydus Cadila.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1861
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment